<clinical_study>
<study_id>
<org_name>
  Amylin
</org_name>
<org_full_name>
  Amylin Pharmaceuticals
</org_full_name>
<org_study_id>
  2993-114
</org_study_id>
<secondary_id>
</secondary_id>
<nct_id>
  NCT00097500
</nct_id>
</study_id>
<brief_title>
<textblock>
Effects  of  Exenatide  and  Insulin  Glargine  in  Subjects  With Type  2  Diabetes  
</textblock>
</brief_title>
<official_title>
<textblock>
A  Phase  3,  Randomized,  Open  Label,  Comparator  Controlled,  Parallel  Group,  Multicenter  Study  to  Compare  the  Effects  of  Exenatide  and  Insulin  Glargine  on  Beta  Cell  Function  and  Cardiovascular  Risk  Markers  in  Subjects  With Type  2  Diabetes  Treated  With Metformin  Who  Have  Not  Achieved  Target  HbA1c  
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Amylin Pharmaceuticals
</agency>
</lead_sponsor>
<sponsor>
<agency>
  Eli Lilly and Company
</agency>
</sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<regulatory_authority>
  Finland: National Agency for Medicines
</regulatory_authority>
<regulatory_authority>
  Netherlands: Medicines Evaluation Board (MEB)
</regulatory_authority>
<regulatory_authority>
  Sweden: Medical Products Agency
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus&#174; injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
  2005-08
</date>
</status_block>
<start_date>
<date>
  2004-09
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<primary_outcome>
  * To compare beta-cell function after intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin.
</primary_outcome>
<secondary_outcome>
  * To compare the effects of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin with respect to various pharmacodynamic measurements as well as safety and tolerability.
</secondary_outcome>
<secondary_outcome>
  * To compare the effects following cessation of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin on various pharmacodynamic measurements.
</secondary_outcome>
<condition>
  Type 2 Diabetes Mellitus
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  exenatide
</primary_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Insulin glargine
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - HbA1c between 6.6% and 9.5%, inclusive.
    - Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.
    - Treated with a stable dose of metformin for at least 3 months prior to screening.  
 
  Exclusion Criteria:
    - Patients previously in a study using exenatide.
    - Treated with oral anti-diabetic medications other than metformin within 3 months of screening.
    - Treated with insulin within 3 months of screening.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
  75
</expected_enrollment>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
  75 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Lisa Porter, MD
</name>
<affiliation>
<agency>
  Amylin Pharmaceuticals
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Helsinki
</city>
<state>
</state>
<zip>
</zip>
<country>
  Finland
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Amsterdam
</city>
<state>
</state>
<zip>
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Goteborg
</city>
<state>
</state>
<zip>
</zip>
<country>
  Sweden
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<keyword>
  diabetes
</keyword>
<keyword>
  exenatide
</keyword>
<keyword>
  exendin-4
</keyword>
<keyword>
  Amylin
</keyword>
<keyword>
  Lilly
</keyword>
<initial_release_date>
  2004-11-24
</initial_release_date>
<last_release_date>
  2005-08-25
</last_release_date>
</clinical_study>
